IP Verse

Syringe - EP3777834

The patent EP3777834 was granted to Novartis on Feb 16, 2022. The application was originally filed on May 30, 2013 under application number EP20198921A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3777834

NOVARTIS
Application Number
EP20198921A
Filing Date
May 30, 2013
Status
Granted And Under Opposition
Jan 14, 2022
Publication Date
Feb 16, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPNov 16, 2022HAMM & WITTKOPPWITHDRAWN
WESSNov 16, 2022SSM SANDMAIRWITHDRAWN
EHLERSNov 15, 2022EISENFUHR SPEISERADMISSIBLE
STRAWMANNov 15, 2022HOFFMANN EITLEADMISSIBLE
KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBBNov 14, 2022KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBBWITHDRAWN
TEVA PHARMACEUTICALSNov 4, 2022ELKINGTON AND FIFEWITHDRAWN

Patent Citations (64) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2005121176
OPPOSITIONEP0738517
OPPOSITIONEP0764450
OPPOSITIONEP0971749
OPPOSITIONEP2047877
OPPOSITIONEP2298392
OPPOSITIONEP2436413
OPPOSITIONEP2682145
OPPOSITIONEP2854762
OPPOSITIONEP3536310
OPPOSITIONJP2000014779
OPPOSITIONJP2001340455
OPPOSITIONJP2002177388
OPPOSITIONJP2004313369
OPPOSITIONJP2009284951
OPPOSITIONJP2012045046
OPPOSITIONJPH0725953
OPPOSITIONUS2003032928
OPPOSITIONUS2003034264
OPPOSITIONUS2005129569
OPPOSITIONUS2005148947
OPPOSITIONUS2005192544
OPPOSITIONUS2007250017
OPPOSITIONUS2009131869
OPPOSITIONUS2009247957
OPPOSITIONUS2010181218
OPPOSITIONUS2011137263
OPPOSITIONUS2012078224
OPPOSITIONUS2012109072
OPPOSITIONUS2602447
OPPOSITIONUS4252118
OPPOSITIONUS4946441
OPPOSITIONUS5173258
OPPOSITIONUS5405326
OPPOSITIONUS5597530
OPPOSITIONUS5607399
OPPOSITIONUS5607400
OPPOSITIONUS5667495
OPPOSITIONUS5688252
OPPOSITIONUS6090081
OPPOSITIONUS7060269
OPPOSITIONUS7678078
OPPOSITIONUS8075535
OPPOSITIONUS8137324
OPPOSITIONWO2004091700
OPPOSITIONWO2006047325
OPPOSITIONWO2007035621
OPPOSITIONWO2008077155
OPPOSITIONWO2009030976
OPPOSITIONWO2011006877
OPPOSITIONWO2014005728
OPPOSITIONWO2019005072
OPPOSITIONWO9413339
OPPOSITIONWO9744068
OPPOSITIONWO9955402
OTHERWO2004091700
SEARCHDE102008005938
SEARCHEP1488818
SEARCHEP2298392
SEARCHUS2006293270
SEARCHUS4946441
SEARCHUS8075535
SEARCHWO2007035621
SEARCHWO2011006877

Non-Patent Literature (NPL) Citations (29) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- ANDREA WAGNER, "Advances in Prefilled Syringe Technology", ITP, (20070000), vol. 24, pages 73 - 75, XP055427527
OPPOSITION- Anonymous, "Components for prefilled syringes ", DATWYLER, (20111001), DATWYLER, (20240318), XP093142376
OPPOSITION- Anonymous, "Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package for Aflibercept injection for the treatment of patients with neovascular (wet0 age-related macular degeneration (AMD)", DTOP-Aflibercept briefing package for advisory meeting, (20110000), pages 1 - 70, XP093002913
OPPOSITION- Anonymous, "Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package for Aflibercept injection for the treatment of patients with neovascular (wet0 age-related macular degeneration (AMD)", DTOP-Aflibercept briefing package for advisory meeting, (20110101), pages 1 - 70, DTOP-Aflibercept briefing package for advisory meeting, (20221129), XP093002913
OPPOSITION- Anonymous, "Glass barrels for injectables", ISO 110410 Prefilled syringes, (20070201), pages 1 - 16, XP093002899
OPPOSITION- Anonymous, "Highlights of prescribing information these highlights do not include all of the information needed to use macugen safely and effectively.", Macugen, (20110700), pages 1 - 10, XP093002555
OPPOSITION- Anonymous, "ISO 11040-4", INTERNATIONAL STANDARD, (20070201), INTERNATIONAL STANDARD, (20221130), XP093003391
OPPOSITION- Anonymous, "ISO 11040-6", INTERNATIONAL STANDARD, (20120401), INTERNATIONAL STANDARD , (20221130), XP093003395
OPPOSITION- Anonymous, "Lucentis - highlights of prescribing information", Lucentis, (20100600), pages 1 - 7, XP093002595
OPPOSITION- Anonymous, "Lucentis''® Material Safety Data Sheet", Genentech, INC., (20090522), pages 1 - 5, XP093002580
OPPOSITION- Anonymous, "Ophthalmic solutions", US Pharmacopeia National Formulary. Vol 11, (20110501), vol. 11, pages 328 - 329, XP093003855
OPPOSITION- Anonymous, "Product information EYLEA® aflibercept (rich)", (20120307), pages 1 - 18, (20220309), XP055899118
OPPOSITION- Anonymous, "PRODUCT INFORMATION FOR PUBLICATION ", THERAPEUTIC GOODS, (20120606), THERAPEUTIC GOODS , (20221201), XP093003793
OPPOSITION- Anonymous, "Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration", N Engl J Med, (20110519), vol. 364, no. 20, pages 1897 - 1908, XP055972148
OPPOSITION- Anonymous, "Stainless steel needle tubing for manufacture of medical devices (ISO 9626:1991 + AMD 1:2001) (including amendment A1:2001); German version EN ISO 9626:1995 + A1:2001", DIN EN ISO 9626 : 2002-03, (20020301), DIN EN ISO 9626 : 2002-03, (20221201), XP093003852
OPPOSITION- Anonymous, "SYRINGES FOR CHROMATOGRAPHIC AND ANALYTICAL APPLICATIONS ", Sigma Aldrich brochure, (20070101), XP093003401
OPPOSITION- Bruno Reuter, Petersen Claudia, Gerresheimer Bünde, Gmbh, Bünde, "Syringe Siliconization Trends, methods, analysis procedures", (20120101), URL: https://pdfs.semanticscholar.org/e940/10e357b30dd015752cb005c15e14fa7dd506.pdf?_ga=2.180808103.1640326775.1579172132-188552557.1579172132, (20200116), XP055658634
OPPOSITION- Cooney Peter, Mamane William G., "Guidance for Industry for the Submission Documentation for Sterilization Process Validation Applications for Human and Veterinary Drug Products", CDR - CVM, (19941101), CDR - CVM, (20221201), XP093003857
OPPOSITION- Denyer Stephen P., Norman A. Hodges, Sean P. Gorman, "Sterilization procedures and sterility assurance", Hugo and Russe ll's pharmaceutical microbiology, (20080101), page 327, 350, XP093003865
OPPOSITION- Gerding H., Timmermann M, "Accuracy and Precision of Intravitreally Injected Ranibi- zumab Doses: An Experimental Study Experimentelle Untersuchungen zur Genauigkeit und Präzision der Dosierung intravitrealer Injektionen von Ranibizumab", Accuracy and Precision… Klin Monatsbl Augenheilkd, (20100420), vol. 227, pages 269 - 272, XP093003872
OPPOSITION- "HIGHLIGHTS OF PRESCRIBING INFORMATION", NDA 21-756/S-018, (20110700), pages 3 - 12, URL: https://www.accessdata.fda.gov/ drugsatfda docs/label/2011/021756s018lbl.pdf, XP093002555
OPPOSITION- Iso, "Sterilization of health care products —Vocabulary of terms used in sterilization and related equipment and process standards. Extract", International Standard ISO 11139 -First edition 2018-08, (20180801), pages 28 - 29, XP055981258
OPPOSITION- Spaeth George L., "lntravitreal injection of drug", Ophthalmic Surgery: Principles and Prac- tice, E-Book, (20110101), pages 511 - 512, XP093003875
OPPOSITION- Website entry of the US Food and Drug administration (FDA, URL: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm256594.htm
OPPOSITION- Website entry of the US Food and Drug administration (FDA, URL: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Dr ugs/DermatoIogicandOphthaImicDrugsAdvisoryCommittee/ucm259141.htm
OPPOSITION- Kim, J.E. ; Mantravadi, A.V. ; Hur, E.Y. ; Covert, D.J., "Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20081201), vol. 146, no. 6, doi:10.1016/j.ajo.2008.07.007, ISSN 0002-9394, pages 930 - 934.e1, XP025681704
OPPOSITION- Lincoff Harvey, Coleman Jackson, Kreissig Ingrid, Richard Gisbert, Chang Stanley, Wilcox Lloyd M., "The Perfluorocarbon Gases in the Treatment of Retinal Detachment", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19830501), vol. 90, no. 5, doi:10.1016/S0161-6420(83)34525-5, ISSN 0161-6420, pages 546 - 551, XP093003853
OPPOSITION- Slocik Joseph M., Dennis Patrick B., Kuang Zhifeng, Pelton Anthony, Naik Rajesh R., "Creation of stable water-free antibody based protein liquids", Communications Materials, (20211201), vol. 2, no. 1, doi:10.1038/s43246-021-00222-2, XP055900234
OPPOSITION- Azad Rajvardhan, Runda Neelam, Kumar Atul, Sharma Yograj, Chandra Parijat, "To Compare Photodynamic Therapy with Ranibizumab vs Photodynamic Therapy with Pegaptanib for Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration", World Journal of Retina & Vitreous, (20120515), vol. 2, doi:10.5005/jp-journals-10020-1024, ISSN 2249-0477, pages 23 - 27, XP093003870

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents